1. The median progression-free survival for trametinib was significantly greater than that for standard-of-care therapy (13 months vs. 7.2 months). ...
1. Both CA125 serum and transvaginal ultrasound annual screening did not significantly reduce deaths due to ovarian or tubal cancer ...
1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus ...
Recent advances have been demonstrated with the administration of intraperitoneal (IP) cisplatin and paclitaxel, where women with stage III ovarian ...
Screening for breech presentation using universal late-pregnancy ultrasonography: A prospective cohort study and cost effectiveness analysis Fetal presentation has long ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.